Core Points - The company has released its 2025 semi-annual report, which includes financial results and future development plans [1][2] - The board of directors confirmed the authenticity, accuracy, and completeness of the report, taking legal responsibility for its content [2] - The board meeting was held on August 25, 2025, with all nine directors participating and unanimously approving the semi-annual report [2] Financial Data - The semi-annual report contains key financial data, although specific figures are not detailed in the provided text [1] - The report has been reviewed by the company's audit committee before being submitted to the board for approval [2] Important Matters - The company has not reported any significant changes in its operating conditions during the reporting period [1] - A resolution was passed to approve a donation of 390,000 RMB by its subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd., to the Jiangxi Red Cross Foundation, which is not expected to significantly impact the company's financial performance [3]

Meeting Overview - The shareholders' meeting was held on August 12, 2025, at the company's conference room in Shanghai [1] - The meeting was presided over by the chairman, Mr. Deng Haibin, and complied with the Company Law and Articles of Association [1] Attendance - All 9 current directors attended the meeting, with some participating via communication due to work commitments [2] - All 4 current supervisors attended, with some also participating via communication [2] - The board secretary and other senior executives were present at the meeting [2] Resolutions Passed - The proposal to cancel the supervisory board and amend the Articles of Association was approved [2] - The proposal to revise certain governance systems of the company was also approved [2] - All proposals received approval from the shareholders' meeting [2] Legal Verification - The meeting was witnessed by Guohao Law Firm, with lawyers Wang Bo and Su Chengzi present [3] - The legal opinion confirmed that the meeting's procedures and voting methods complied with relevant laws and regulations, and the resolutions made were valid [3] Announcement - The announcement was issued by Shanghai Haixin Group Co., Ltd. on August 13, 2025, under the securities code 600851 [5]

Core Viewpoint - Shanghai Haixin Group Co., Ltd. has successfully completed the transfer of 51.3249% equity in Shanghai Haixin Pharmaceutical Co., Ltd. to Chongqing Huisheng Yunjian Business Information Consulting Center for a total consideration of 23.0494 million yuan [2][3]. Group 1: Transaction Overview - The board of directors approved the equity transfer on September 25, 2023, and authorized the management to handle the transaction [3]. - The total transaction price for the equity transfer was set at 23.0494 million yuan [3]. - As of the announcement date, Haixin Asset has received a total of 21.8969 million yuan from Huisheng Yunjian, which accounts for 95% of the agreed transfer price [3]. Group 2: Payment Progress - The third payment of 1.1525 million yuan was recently received, completing the total payment for the equity transfer [4]. - The total amount received from Huisheng Yunjian for the equity transfer is now 23.0494 million yuan, marking the full recovery of the transfer price [4].

Group 1 - The company will hold its 2024 Annual General Meeting on June 18, 2025, at 14:00 in Shanghai [1][4] - The voting method for the meeting will combine on-site and online voting [1] - The online voting system will be provided by the Shanghai Stock Exchange, with voting available from 9:15 to 15:00 on the day of the meeting [2][7] Group 2 - The meeting will include a report from the independent directors for the 2024 fiscal year [5] - All proposals for the meeting were approved during the board and supervisory meetings held on April 17, 2025 [6] - There are no special resolutions or related party voting issues for this meeting [7] Group 3 - Shareholders must register to attend the meeting, with registration available on June 16, 2025 [16] - The company provides a reminder service for small and medium investors to ensure participation [8] - Shareholders holding multiple accounts can vote through any of their accounts, but repeated votes will be counted only once [9][10]

Financial Data and Indicators - The basic earnings per share for Q1 2025 is 0.0274 yuan, representing a 2.62% increase compared to Q1 2024, which was 0.0267 yuan [1] - The net asset per share increased by 8.26% to 3.54 yuan in Q1 2025 from 3.27 yuan in Q1 2024 [1] - The net profit for Q1 2025 is 0.33 billion yuan, a 3.13% increase from 0.32 billion yuan in Q1 2024 [1] - The return on equity decreased by 6.17% to 0.76% in Q1 2025 from 0.81% in Q1 2024 [1] - The operating revenue for Q1 2025 is 2.02 billion yuan, down by 3.35% from 2.09 billion yuan in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 50,820.45 million shares, accounting for 42.1% of the circulating shares, with a decrease of 0.50 million shares compared to the previous period [1] - New entrants among the top shareholders include Hunan Ningrui Investment Partnership (11.73%), Shanghai Songjiang Dongjing Industrial Company (6.80%), and Ningbo Meishan Free Trade Port Area Xinxin Private Fund Management Partnership (4.97%) [2] - The previous top shareholders have exited, including Hunan Ningrui Investment Partnership and Shanghai Songjiang Dongjing Industrial Company [2] Dividend Distribution - The company will not distribute or transfer any dividends this time [3]

证券代码：600851/900917 证券简称：海欣股份/海欣 B 股 公告编号：2024-024 上海海欣集团股份有限公司 关于参加上海辖区上市公司 2024 年投资者 网上集体接待日暨中报业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可提前通过公司邮箱 600851@haixin.com 进行提问。公司将在说明会 上对投资者普遍关注的问题进行回答。 上海海欣集团股份有限公司（以下简称"公司"）已于 2024 年 8 月 24 日发布公 司 2024 年半年度报告。为进一步加强与投资者的互动交流，公司将参加由上海上市 公司协会与深圳市全景网络有限公司联合举办的"2024 年上海辖区上市公司投资者集 体接待日暨中报业绩说明会"，现将相关事项公告如下： 一、 说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2024 年半年度的经营成果及 财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就投资 者普遍关注的问题进行回答。 1 会议召开时间：2024 年 9 月 ...

Company Profile and Key Financial Indicators [Company Information](index=4&type=section&id=Company%20Information) Shanghai Haixin Group Co, Ltd is a listed company engaged in pharmaceuticals, property leasing, textiles, financial investment, and commodity trading - Basic company information includes its Chinese name “上海海欣集团股份有限公司”, A-share ticker “海欣股份”, B-share ticker “海欣B股”, and legal representative, Fei Minhua[12](index=12&type=chunk)[16](index=16&type=chunk) [Key Accounting Data and Financial Indicators](index=5&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) Revenue fell 34.98% due to the deconsolidation of Haixin Pharmaceutical and reduced trade, while net cash flow from operations surged 1687.11% from lower tax payments 2024 H1 Key Accounting Data | Key Accounting Data | Current Period (Jan-Jun) (Yuan) | Prior Year Period (Yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 406,499,814.08 | 625,159,485.96 | -34.98 | | Net Profit Attributable to Shareholders | 101,781,616.57 | 101,676,991.04 | 0.10 | | Net Profit Attributable to Shareholders (Non-recurring items deducted) | 99,477,853.24 | 104,421,712.71 | -4.73 | | Net Cash Flow from Operating Activities | 66,627,801.39 | 3,728,237.70 | 1,687.11 | | **Asset Status** | **End of Current Period** | **End of Prior Year** | **Change from Prior Year-End (%)** | | Net Assets Attributable to Shareholders | 3,886,419,387.36 | 3,965,055,449.29 | -1.98 | | Total Assets | 4,870,678,774.69 | 4,910,625,159.28 | -0.81 | 2024 H1 Key Financial Indicators | Key Financial Indicator | Current Period (Jan-Jun) | Prior Year Period | YoY Change | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (Yuan/Share) | 0.0843 | 0.0842 | 0.12% | | Weighted Average Return on Equity (%) | 2.5344 | 2.6108 | Decrease of 0.0764 percentage points | - The decline in operating revenue was mainly due to the deconsolidation of Haixin Pharmaceutical (a decrease of 80.27 million Yuan) and a reduction in commodity trading revenue (77.18 million Yuan)[19](index=19&type=chunk) - The significant increase in net cash flow from operating activities was primarily due to a **56.29 million Yuan reduction** in various tax payments[20](index=20&type=chunk) [Non-recurring Profit and Loss Items and Amounts](index=6&type=section&id=Non-recurring%20Profit%20and%20Loss%20Items%20and%20Amounts) Non-recurring profit and loss for the period totaled 2.30 million Yuan, mainly from fair value changes and disposals of financial assets and liabilities Non-recurring Profit and Loss Items | Item | Amount (Yuan) | | :--- | :--- | | Gains/Losses on Disposal of Non-current Assets | -37,965.91 | | Government Grants Recognized in Current Profit or Loss | 891,877.80 | | Fair Value Changes and Disposal Gains/Losses on Financial Assets/Liabilities | 2,599,130.54 | | Other Non-operating Income and Expenses | -299,104.54 | | Other Items Meeting the Definition of Non-recurring P&L | 216,686.29 | | **Total** | **2,303,763.33** | Management Discussion and Analysis [Report on the Company's Industry and Main Business during the Reporting Period](index=6&type=section&id=Report%20on%20the%20Company's%20Industry%20and%20Main%20Business%20during%20the%20Reporting%20Period) The company operates across five segments: pharmaceuticals, property management, textiles, financial investment, and commodity trading - The company's main business segments include: - **Pharmaceuticals**: Primarily focused on chemical drug production and sales - **Industrial Plant and Property Leasing**: Manages and leases existing properties - **Textiles**: Engaged in the R&D, production, and sale of plush fabrics and apparel - **Financials**: Holds equity stakes in Changjiang Securities and Changxin Asset Management - **Commodity Trading**: Participates in upstream and downstream supply chain procurement and sales[25](index=25&type=chunk) [Discussion and Analysis of Operations](index=7&type=section&id=Discussion%20and%20Analysis%20of%20Operations) In H1 2024, the company achieved revenue of 407 million Yuan (-34.98% YoY) and net profit of 102 million Yuan (+0.10% YoY) amid a complex environment - **Pharmaceuticals Segment**: Holding pharmaceutical manufacturing companies achieved a combined operating revenue of **236 million Yuan**, down 15.00% YoY, and a combined net profit attributable to the parent of **10.57 million Yuan**, down 5.29% YoY[27](index=27&type=chunk)[28](index=28&type=chunk) - **Property Segment**: Maintained an occupancy rate of around **90%** despite market downturns, generating self-operated leasing income of **41.99 million Yuan** and a net operating profit of **25.83 million Yuan**, up 2.63% YoY[29](index=29&type=chunk)[30](index=30&type=chunk) - **Textiles Segment**: Continued its contraction and adjustment, with revenue of **63.49 million Yuan** (-25.29% YoY), but achieved a turnaround in net profit attributable to the parent, realizing a profit of **44,900 Yuan**[31](index=31&type=chunk) [Key Operations during the Reporting Period](index=8&type=section&id=Key%20Operations%20during%20the%20Reporting%20Period) Significant financial metric changes occurred, including decreased revenue and costs, a 78.60% drop in finance costs, and a 1687.11% surge in operating cash flow Analysis of Key Items in Financial Statements | Item | Current Period (Yuan) | Prior Year Period (Yuan) | Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 406,499,814.08 | 625,159,485.96 | -34.98 | Deconsolidation of Haixin Pharmaceutical and reduced commodity trading revenue | | Operating Costs | 169,159,793.18 | 332,617,406.22 | -49.14 | Deconsolidation of Haixin Pharmaceutical and reduced commodity trading costs | | Finance Costs | -4,279,137.94 | -2,395,882.98 | -78.60 | Reduced interest expense and increased foreign exchange gains | | Net Cash Flow from Operating Activities | 66,627,801.39 | 3,728,237.70 | 1,687.11 | Decrease in various tax payments | | Net Cash Flow from Investing Activities | -107,248,544.75 | 85,189,284.71 | -225.89 | Decrease in investment redemptions (wealth management products) | | Net Cash Flow from Financing Activities | -20,484,169.35 | -1,622,224.39 | 1,162.72 | Reduced borrowing by Nanjing Plush | Performance of Major Subsidiaries and Investees | Company Name | Business Nature | Net Profit (CNY 10,000) | Investment Income (CNY 10,000) | % of Company's Net Profit | | :--- | :--- | :--- | :--- | :--- | | **Holding Subsidiaries** | | | | | | Jiangxi Gannan Haixin Pharmaceutical | Pharmaceuticals | 2,019.15 | - | - | | Xi'an Haixin Pharmaceutical | Pharmaceuticals | -346.92 | - | - | | Nanjing Haixin Lining Plush | Textiles | 290.22 | - | - | | **Investee Companies** | | | | | | Changjiang Securities | Financials | - | 2,978.40 | 29.26% | | Changxin Asset Management | Financials | - | 1,720.97 | 16.91% | | Jiangsu Suzhong Pharmaceutical Group | Pharmaceuticals | - | 1,271.17 | 12.49% | | Jiangsu Suzhong Health Technology | Health Services | - | 1,315.72 | 12.93% | - The company faces key risks including market competition, policy changes in healthcare and finance, technological iteration, environmental protection, and quality control[46](index=46&type=chunk)[47](index=47&type=chunk)[48](index=48&type=chunk)[50](index=50&type=chunk)[51](index=51&type=chunk) Corporate Governance [Summary of Shareholders' Meetings](index=12&type=section&id=Summary%20of%20Shareholders'%20Meetings) The 2023 Annual General Meeting was held on June 20, 2024, approving the annual report, profit distribution plan, and amendments to the Articles of Association - The 2023 Annual General Meeting approved multiple resolutions, including the "Company's 2023 Annual Report," the "2023 Profit Distribution Plan," and the "Resolution on Amending the <Articles of Association> and Related Policies"[56](index=56&type=chunk)[58](index=58&type=chunk) [Changes in the Company's Directors, Supervisors, and Senior Management](index=13&type=section&id=Changes%20in%20the%20Company's%20Directors,%20Supervisors,%20and%20Senior%20Management) Significant leadership changes occurred with the election of the 11th Board of Directors and Supervisory Committee and the appointment of new senior management - On July 15, 2024, the company completed its leadership transition, electing the 11th Board of Directors and Supervisory Committee[60](index=60&type=chunk) - On the same day, the 11th Board of Directors appointed Mr. Ren Xiaowei as President and appointed or re-appointed several Vice Presidents, a CFO, and a Board Secretary[60](index=60&type=chunk) Environmental and Social Responsibility [Environmental Information](index=14&type=section&id=Environmental%20Information) Three subsidiaries are designated as key pollutant-discharging units, with all facilities operating normally and no environmental penalties received during the period - The company's subsidiaries Gannan Haixin, Shaanxi Pharmaceutical, and Baoding Plush are listed as **key pollutant-discharging units**[65](index=65&type=chunk) - Each key unit is equipped with corresponding wastewater and exhaust gas treatment facilities, which are operating normally to ensure compliant emissions[68](index=68&typechunk)[69](index=69&type=chunk) - All three subsidiaries hold valid pollutant discharge permits and have formulated emergency response plans for environmental incidents[70](index=70&type=chunk)[71](index=71&type=chunk) Significant Matters [Fulfillment of Commitments](index=19&type=section&id=Fulfillment%20of%20Commitments) Historical commitments related to share reform and refinancing, including share sale disclosures and avoiding horizontal competition, were strictly fulfilled - Company shareholders continued to fulfill commitments made during share reform and refinancing regarding share sale disclosures and the avoidance of horizontal competition[76](index=76&type=chunk) [Significant Guarantees](index=21&type=section&id=Significant%20Guarantees) The company had no external guarantees; guarantees for subsidiaries totaled 13.75 million Yuan, representing 0.35% of the company's net assets Summary of Guarantees | Guarantee Category | Amount Incurred (CNY 10,000) | Balance at Period-End (CNY 10,000) | | :--- | :--- | :--- | | External Guarantees | 0 | 0 | | Guarantees for Subsidiaries | 1,375 | 1,375 | | **Total Guarantees** | **1,375** | **1,375** | | Total Guarantees as % of Net Assets | - | 0.35% | Share Capital Changes and Shareholder Information [Changes in Share Capital](index=22&type=section&id=Changes%20in%20Share%20Capital) The company's total number of shares and share capital structure remained unchanged during the reporting period - During the reporting period, the company's total number of shares and share capital structure did not change[83](index=83&type=chunk) [Shareholder Information](index=22&type=section&id=Shareholder%20Information) As of the period-end, the company had 60,807 common shareholders, with the top two shareholders and their concerted parties holding a combined 14.98% - As of the period-end, the company had **60,807 common shareholders**, comprising 30,887 A-share holders and 29,920 B-share holders[84](index=84&type=chunk) Top Ten Shareholders | Shareholder Name | Shares Held at Period-End | Percentage (%) | | :--- | :--- | :--- | | 1. Hunan Ningrui Investment Partnership (LP) | 141,528,801 | 11.73 | | 2. Shanghai Songjiang Dongjing Industrial Corp | 82,082,000 | 6.80 | | 3. Jiaxing Qingxin Zhengmao Equity Investment Partnership | 60,000,000 | 4.97 | | 4. Shanghai Toys Import & Export Co, Ltd | 39,300,000 | 3.26 | | 5. Hunan Caixin Economic Investment Co, Ltd | 39,288,210 | 3.25 | - Shareholder relationship disclosure: Hunan Ningrui Investment Partnership (LP) and Hunan Caixin Economic Investment Co, Ltd are **concerted parties**[87](index=87&type=chunk) Financial Report [Financial Statements](index=25&type=section&id=Financial%20Statements) The unaudited H1 2024 report shows total assets of 4.87 billion Yuan, net profit of 102 million Yuan, and operating cash flow of 66.63 million Yuan - This semi-annual report is **unaudited**[6](index=6&type=chunk) Consolidated Financial Statement Core Data (As of June 30, 2024 / For Jan-Jun 2024) | Indicator | Amount (CNY) | | :--- | :--- | | **Balance Sheet:** | | | Total Assets | 4.87 billion | | Total Liabilities | 0.82 billion | | Equity Attributable to Parent Company | 3.89 billion | | **Income Statement:** | | | Operating Revenue | 406 million | | Net Profit Attributable to Parent Company | 102 million | | Basic Earnings Per Share | 0.0843 Yuan | | **Cash Flow Statement:** | | | Net Cash Flow from Operating Activities | 66.63 million | | Net Cash Flow from Investing Activities | -107.25 million | | Net Cash Flow from Financing Activities | -20.48 million | [Notes to Consolidated Financial Statement Items](index=74&type=section&id=Notes%20to%20Consolidated%20Financial%20Statement%20Items) Notes detail account balances, including 1.21 billion Yuan in long-term equity investments and 844 million Yuan in investment properties at fair value - The top five accounts receivable balances account for **28.73% of the total**, with significant bad debt provisions made for receivables from Nanjing Hongli Trading and Dumont (Shanghai) Trading[308](index=308&type=chunk) - Long-term equity investments primarily include investments in joint venture Shanghai Jinxin United Development (book value **564 million Yuan**) and associates Changxin Asset Management (**392 million Yuan**), Suzhong Pharmaceutical (**111 million Yuan**), and Suzhong Health Technology (**131 million Yuan**)[336](index=336&type=chunk) - Other equity instrument investments mainly consist of the investment in Changjiang Securities, with a period-end book value of **1.20 billion Yuan**[338](index=338&type=chunk) - Construction in progress is mainly for the Haixin Intelligent Industrial Park project, with a book balance of **202 million Yuan** and a budget completion rate of approximately **80.59%**[351](index=351&type=chunk)[354](index=354&type=chunk) [Segment Information](index=138&type=section&id=Segment%20Information) The company reports five segments, with the medical segment being the largest revenue contributor and the investment segment the most profitable in H1 2024 H1 2024 Financial Information by Segment (Unit: Yuan) | Item | Investment (Seg 1) | Textiles (Seg 2) | Medical (Seg 3) | Trading (Seg 4) | Industrial Park (Seg 5) | | :--- | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 3,153,172.41 | 63,486,257.77 | 235,908,582.24 | 63,499,778.76 | 47,826,490.57 | | Net Profit | 101,498,815.69 | -516,490.03 | 15,617,869.77 | 1,084,507.71 | 11,105,046.10 |

Financial Performance - The company's operating revenue for the year 2023 reached CNY 4,988,253.83, an increase from CNY 3,355,622.30 in 2022, representing a growth of approximately 48.6%[31] - The net profit for 2023 was CNY 99,119,499.26, compared to CNY 166,240,576.08 in 2022, indicating a decrease of about 40.3%[31] - Basic earnings per share for 2023 were CNY 0.1376, slightly up from CNY 0.1359 in 2022[30] - The company reported investment income of CNY 162,678,613.50 for 2023, down from CNY 214,660,127.20 in 2022, a decline of approximately 24.2%[31] - The total operating profit for 2023 was CNY 94,911,546.44, a decrease from CNY 157,671,625.00 in the previous year, reflecting a decline of about 39.8%[31] - The total profit amounted to ¥207,181,178.48, a decrease from ¥230,329,731.65 in the previous period, reflecting a decline of approximately 10%[34] - Net profit for the period was ¥192,107,136.51, compared to ¥198,382,453.82 in the prior year, indicating a decrease of about 3%[34] - The net profit attributable to shareholders of the parent company was ¥166,030,649.74, slightly up from ¥164,056,061.10, showing an increase of approximately 1.2%[34] - The total comprehensive income for the period was ¥202,115,102.45, contrasting with a loss of ¥206,921,483.57 in the previous period[34] - The total comprehensive income for the year was 176.04 million yuan, with a net profit distribution of -64.23 million yuan[70] Cash Flow and Assets - The cash flow from operating activities was 1,214.46 million yuan, down from 1,547.99 million yuan in the previous year[65] - Cash and cash equivalents increased to ¥509.55 million from ¥420.29 million, representing a growth of approximately 21% year-over-year[174] - Total current assets decreased from 1,087,716,787.09 to 993,987,824.74, a decline of approximately 8.6%[178] - Long-term equity investments increased from 1,127,034,374.09 to 1,181,061,183.99, representing a growth of about 4.8%[178] - Total liabilities decreased from 911,215,769.39 to 775,286,878.90, a reduction of approximately 14.9%[180] - Total owner's equity increased from 4,018,848,320.64 to 4,135,338,280.38, reflecting an increase of about 2.9%[180] - Cash and cash equivalents rose from 228,011,028.77 to 290,632,320.87, an increase of approximately 27.5%[186] - Total assets decreased slightly from 4,930,064,090.03 to 4,910,625,159.28, a decrease of about 0.4%[180] Expenses and Costs - Total operating costs for 2023 were $1,116,082,358.77, down about 21.3% from $1,416,807,804.41 in 2022[190] - Operating profit for 2023 was $210,512,398.60, a decline of around 8.4% from $229,889,547.81 in 2022[190] - Research and development expenses increased to $23,109,998.20 in 2023, compared to $22,672,328.29 in 2022, reflecting a growth of approximately 1.9%[190] - Sales expenses decreased to $327,042,249.54 in 2023, a reduction of about 25% from $434,867,383.46 in 2022[190] - Management expenses were $123,438,537.06 in 2023, down from $145,232,641.24 in 2022, indicating a decrease of approximately 15%[190] - Tax expenses for 2023 were $17,989,872.04, significantly lower than $44,298,106.17 in 2022, marking a decrease of about 59.5%[190] - Other income for 2023 was $2,838,674.31, down from $6,669,192.60 in 2022, reflecting a decline of approximately 57.5%[190] - Financial expenses showed a net income of -$7,073,168.60 in 2023, compared to -$5,437,487.47 in 2022, indicating an increase in financial costs[190] Shareholder Information - The proposed cash dividend is ¥0.65 per 10 shares, totaling ¥78,458,684.98, which is 47.26% of the net profit attributable to shareholders[56] - There were no significant changes in the shareholding structure during the reporting period, with the largest shareholder holding 11.73% of the shares[20] - The company reported no guarantees provided to external parties, while guarantees to subsidiaries totaled ¥1,375.00, representing 0.35% of the company's net assets[35] - The company has not incurred any new guarantees during the reporting period, maintaining a stable financial position[35] Strategic Initiatives - The company plans to continue its market expansion and product development strategies in the upcoming fiscal year[34] - The company is focusing on enhancing its corporate culture and party building to boost team spirit and business development[60] - The company is committed to improving risk prevention effectiveness through optimized internal control systems[60] - The company emphasizes the importance of innovation in technology, products, and market strategies to remain competitive in the increasingly challenging pharmaceutical industry[98] - The company is actively engaged in research and development to enhance product quality and efficacy, driven by government policies supporting pharmaceutical innovation[98] - The company has a commitment to expanding its market presence and exploring new investment opportunities in line with national industrial policies[74] - Future outlook includes plans for market expansion and potential acquisitions to enhance growth opportunities[151] - The company is exploring strategic partnerships to leverage synergies and enhance market presence[151] Compliance and Governance - The company has strengthened its internal management mechanisms and governance levels in compliance with legal regulations[60] - The financial report was approved for publication on April 18, 2024, indicating the company's adherence to regulatory requirements[74] - The company has maintained its accounting policies consistent with the previous year, ensuring comparability in financial reporting[110] - The financial statements have been prepared in accordance with applicable accounting standards, ensuring transparency and accuracy[110]

Financial Performance - Q3 2023 revenue was CNY 321,539,166.53, a decrease of 22.03% year-over-year[3] - Net profit attributable to shareholders was CNY 24,262,874.13, down 46.13% compared to the same period last year[3] - Basic earnings per share decreased by 46.11% to CNY 0.0201[4] - Total operating revenue for the first three quarters of 2023 was CNY 946,698,652.49, a decrease of 9.8% compared to CNY 1,048,902,061.80 in the same period of 2022[17] - Net profit for the first three quarters of 2023 was CNY 131,618,732.09, a decline of 27.6% from CNY 181,714,625.37 in 2022[18] - Earnings per share for the third quarter were CNY 0.1043, down from CNY 0.1410 in the previous year[19] Assets and Liabilities - Total assets increased by 2.90% to CNY 5,072,793,296.77 compared to the end of the previous year[4] - As of September 30, 2023, the total assets of the company amounted to CNY 5,072,793,296.77, an increase from CNY 4,930,064,090.03 at the end of 2022, representing a growth of approximately 2.88%[13] - The total liabilities decreased slightly to CNY 911,120,500.25 from CNY 911,215,769.39, indicating a marginal reduction of approximately 0.01%[15] - The total current liabilities decreased to CNY 441,054,176.94 from CNY 472,471,150.87, showing a decline of approximately 6.64%[15] - The company's total equity attributable to shareholders increased to CNY 4,011,605,322.87 from CNY 3,843,579,153.36, representing a growth of 4.4%[16] Cash Flow - Cash flow from operating activities was CNY 31,746,564.80, an increase of 7.21% year-over-year[3] - Operating cash flow for the first nine months of 2023 was CNY 35,474,802.50, a decrease from CNY 40,002,254.43 in the same period of 2022, reflecting a decline of approximately 3.3%[24] - Total cash inflow from operating activities was CNY 1,024,531,608.07, compared to CNY 1,154,783,645.74 in the previous year, indicating a decrease of about 11.2%[24] - Cash inflow from investment activities increased to CNY 864,504,202.52 from CNY 737,641,448.98, representing a growth of approximately 17.2%[25] - Net cash flow from investment activities was CNY 146,844,967.83, up from CNY 82,160,513.41, showing an increase of about 78.8%[25] - Cash inflow from financing activities totaled CNY 71,079,404.26, compared to CNY 64,679,105.50, marking an increase of approximately 9.3%[25] - Net cash flow from financing activities was negative at CNY -52,562,278.08, worsening from CNY -44,648,448.62 in the previous year[25] - The ending balance of cash and cash equivalents was CNY 551,312,552.69, up from CNY 404,489,751.26, reflecting an increase of about 36.3%[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 64,114[9] - The top shareholder, Shenzhen Ningrui Investment Management Enterprise, holds 11.73% of the shares[9] Operational Insights - The company plans to focus on improving operational efficiency and exploring new market opportunities[7] - The company has not disclosed any new product developments or market expansion strategies in the current report[12] Other Financial Metrics - The company reported a decrease in investment income from associates, contributing to the decline in net profit[7] - Investment income for the first three quarters was CNY 115,566,685.23, down from CNY 175,179,431.91, indicating a decrease of 34.0%[18] - Other comprehensive income after tax for the third quarter was CNY 94,646,632.77, a significant recovery from a loss of CNY 429,659,513.94 in the previous year[18] - The company reported a decrease in sales expenses to CNY 288,897,754.42 from CNY 372,198,510.68, a reduction of 22.5%[17] - Management expenses decreased to CNY 88,434,728.03 from CNY 100,047,385.68, reflecting a decline of 11.6%[17] - The company's accounts receivable decreased to CNY 149,941,986.02 from CNY 174,382,888.61, a reduction of about 13.96%[13] - The company's inventory decreased to CNY 79,049,664.55 from CNY 89,520,866.14, reflecting a decline of approximately 11.7%[14] - The company reported a significant increase in other receivables, rising to CNY 43,795,581.05 from CNY 35,091,523.76, an increase of approximately 24.5%[14] - Total cash outflow from investment activities was CNY 717,659,234.69, compared to CNY 655,480,935.57, representing an increase of about 9.5%[25] - Cash received from the recovery of investments was CNY 787,638,163.43, compared to CNY 625,083,307.80, indicating an increase of approximately 26%[24] - Cash received from other operating activities was CNY 61,963,637.42, significantly higher than CNY 35,306,486.61, showing an increase of approximately 75.9%[24] - Non-recurring gains and losses totaled CNY -1,508,906.34 for the current period[6]

Group 1: Meeting Details - The meeting is scheduled for September 7, 2023, from 14:00 to 16:30 [3] - The location for the meeting is the "Panorama Roadshow" website (http://rs.p5w.net) [5] - The meeting will be conducted in an interactive online format [4] Group 2: Participation and Interaction - Investors can participate by logging into the "Panorama Roadshow" website or through the WeChat public account: Panorama Finance [6] - Investors are encouraged to submit questions in advance via a QR code provided in the announcement [3] - The company will address commonly asked questions during the performance briefing [4] Group 3: Company Representatives - Key participants include Chairman Fei Minhua, Independent Director Li Zhijun, President and Secretary Ren Xiaowei, and CFO Zhu Xifeng [6] Group 4: Contact Information - For inquiries, investors can contact the Secretary Office at 021-57698031 or via email at 600851@haixin.com [7] - Post-event, details of the meeting and its main content will be available on the "Panorama Roadshow" website [7]